Breaks Categories: Stock Spotlights

TuesdayJan 03, 2017 1:03 pm

NetworkNewsBreaks – Mindful of “Tap and Go” Payment Trend, Net Element (NASDAQ: NETE) Fine-tunes Value-added Services

Unified Payments, a TOT Group company owned by Net Element, Inc. (NASDAQ: NETE), provides secure mobile payments with value added services, honing its focus on increasing demands for specific services within the $180 billion mobile payments industry. “With ‘tap and go’ payments becoming more and more popular, customers expect this service to be available to them. As a result, simply paying via mobile is no longer the key driver for adoption of this relatively new payment method. The focus for mobile payments “is shifting from changing the payments process into a ‘buying experience’,” according to Mobile Payments Today (http://nnw.fm/Y4ktf). With…

Continue Reading

TuesdayJan 03, 2017 1:00 pm

NetworkNewsBreaks – New Age Beverages Corp. (NBEV) Aims for Leading Spot in Niche of Global Beverage Industry

New Age Beverages (OTC: NBEV) is focused on becoming the world’s largest healthy functional beverage company. In November, New Age posted third quarter net sales of $13.4 million, up 10% from the year prior. The company's third quarter EBITDA of $446,205 represents a year-over-year increase of 120%. In its earnings statement, the company also noted its consolidation agreement with Marley Beverage Company, which doubled the sales footprint for both companies and increased the portfolio of brands. Though the two companies will continue to operate as separate financial entities, New Age noted that the revenues of the combined group totals $70 million.…

Continue Reading

TuesdayJan 03, 2017 11:01 am

NetworkNewsBreaks – VBI Vaccines, Inc. (NASDAQ: VBIV) Aims to Halt Global Spread of Hepatitis B

VBI Vaccines (NASDAQ: VBIV) develops next generation vaccines to address unmet needs in infectious disease and immuno-oncology. The commercial-stage company recently received $23.6 million in financing to advance its growing pipeline, which includes its Sci-B-Vac™ hepatitis B vaccine. Globally, more than two billion people show serological evidence of hepatitis B virus (HBV), which results in approximately 780,000 HBV-related deaths each year. While second-generation HBV vaccines contain only one surface antigen, Sci-B-Vac™ contains three viral surface antigens. This composition may provide more opportunities for the immune system to respond with antibodies that can recognize one or more components of the hepatitis…

Continue Reading

TuesdayJan 03, 2017 10:58 am

NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) is Playing a Part in U.S. Cancer Moonshot Initiative

Pressure BioSciences (OTCQB: PBIO) is playing a major role in the war on cancer. Three out of its first five next-generation PCT-based instrument systems have been snapped up by the ProCan lab at the Children's Medical Research Institute in Australia. U.S. Vice President Joe Biden recently named the ProCan facilities an official collaborator in the United States' initiative - known as Cancer Moonshot (CM) - to accelerate the development of combination immunotherapies in cancer treatment. The CM program arose after Biden, whose son succumbed to the disease in 2015, promised a "moonshot" to attack cancer. The CM program has garnered…

Continue Reading

ThursdayDec 29, 2016 12:36 pm

NetworkNewsBreaks – Remark Media (NASDAQ: MARK), Alibaba Team Up to Introduce AI-based Tech to Chinese Market

Remark Media (NASDAQ: MARK) was recently selected to provide its artificial intelligence (AI) technologies to the developer network of Alibaba Cloud, the cloud computing segment of Alibaba Group (NYSE: BABA). The partnership will consist of Remark providing its advanced facial recognition and image classification services, leveraging its proprietary KanKan Data Intelligence Platform, to Alibaba Cloud's "AI-based Robotic Vision Ecosystem Union." Remark will also provide its turnkey AI platform as a service to companies or individuals requiring assistance with integrating the technology into their own models. "We are excited to expand our relationship with Alibaba Group by becoming a close technology…

Continue Reading

WednesdayDec 28, 2016 3:08 pm

NetworkNewsBreaks – iCAD, Inc. (NASDAQ: ICAD) Utilizes Proprietary Algorithm and Artificial Intelligence with PowerLook Tomo Detection

iCAD (NASDAQ: ICAD) provides advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer. Breast cancer is the most common cancer in women, regardless of race or ethnicity. According to the American Cancer Society, 292,130 women were diagnosed with breast cancer in the U.S. in 2015 alone. In an effort to help shrink fatal outcomes of these statistics, iCAD recently launched PowerLook Tomo Detection, which is designed to make reading digital breast tomosynthesis scans (an advanced type of mammogram that can offer better cancer detection, fewer call backs and greater peace of mind) less…

Continue Reading

WednesdayDec 28, 2016 1:22 pm

NetworkNewsBreaks – Valeritas Holdings, Inc. (VLRX) Improving Top and Bottom Lines with Smart Marketing

Valeritas Holdings, Inc. (OTCQB: VLRX) is on track to break through the $20 million revenue ceiling if it keeps up its multi-channel marketing maneuvers. Gross margin is likely to remain at its current 35 percent level in 2017 but will likely increase as revenues increase in 2018, and the company’s bottom line is improving as sales force efficiencies from its new marketing approach take effect. In fact, with fewer sales reps, Valeritas is selling more. Its V-Go® is the only FDA-cleared single-use, fully disposable mechanical insulin delivery device with basal (background) and bolus (mealtime) capability available in the U.S. market.…

Continue Reading

WednesdayDec 28, 2016 12:29 pm

NetworkNewsBreaks – Micronet (NASDAQ: MICT) Trades Higher on TREQr5 $1.06M Continuous Purchase Order

Micronet Enertec Technologies (NASDAQ: MICT) is trading 24% higher after the company this morning said Micronet, its mobile resource management subsidiary, received a continuous purchase order from a fleet management solutions provider for its newly released TREQr5 product. TREQr5 is an innovative ruggedized telematics android on-board computer enhanced for Internet of Things (IOT) and fleet management applications. The purchase order is valued at approximately $1,060,000 and the company anticipates fulfillment by the end of Q1 2017. "We are very pleased to continue our momentum and to receive such a significant purchase order from an established customer and to advance development…

Continue Reading

ThursdayDec 22, 2016 12:51 pm

NetworkNewsBreaks – Second Sight (NASDAQ: EYES): UK Government Greenlights Funding for Argus II “Bionic Eye” Implants

Second Sight Medical Products (NASDAQ: EYES) has made a groundbreaking achievement after advisors issued a positive recommendation to the UK Government’s healthcare funding authority for specialized services in England. For the first time in the UK, the publicly funded NHS system will fund blind patients with Retinitis Pigmentosa (RP) to receive treatment with Second Sight’s innovative Argus® II Retinal Prosthesis System (Argus II) “bionic eye.” A selective group of severely blind patients with RP will have access to Argus II, the world’s first and only routinely used treatment for severe blindness. The hospitals and Second Sight will provide follow up,…

Continue Reading

WednesdayDec 21, 2016 1:16 pm

NetworkNewsBreaks – Calithera Biosciences, Inc. (NASDAQ: CALA), Bristol-Myers Squibb (NYSE: BMY) Collaborate to Assess Combination of Opdivo, CB-839

Calithera Biosciences (NASDAQ: CALA) and Bristol-Myers Squibb (NYSE: BMY) have entered into a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Calithera’s CB-839 in patients with clear cell renal cell carcinoma (ccRCC). Preclinical data suggest that CB-839 – currently in phase 1/2 clinical studies - may enhance the effects of, and reverse tumor resistance to checkpoint inhibitors by altering the immune-suppressive microenvironment and encouraging an anti-tumor immune response. Opdivo is designed to overcome immune suppression. Under the collaboration, Calithera and Bristol-Myers will explore the potential of combining their agents with the goal of achieving improved and continual…

Continue Reading